Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program

English version České info

Weight-loss interventions generally improve lipid profiles and reduce cardiovascular disease risk, but effects are variable and may depend on genetic factors. We performed a genetic association analysis of data from 2,993 participants in the Diabetes Prevention Program to test the hypotheses that a genetic risk score (GRS) based on deleterious alleles at 32 lipid-associated single-nucleotide polymorphisms modifies the effects of lifestyle and/or metformin interventions on lipid levels and nuclear magnetic resonance (NMR) lipoprotein subfraction size and number. Twenty-three loci previously associated with fasting LDL-C, HDL-C, or triglycerides replicated (P = 0.04–1×10⁻¹⁷). Except for total HDL particles (r = −0.03, P = 0.26), all components of the lipid profile correlated with the GRS (partial |r| = 0.07–0.17, P = 5×10⁻⁵–1×10⁻¹⁹). The GRS was associated with higher baseline-adjusted 1-year LDL cholesterol levels (β = +0.87, SEE±0.22 mg/dl/allele, P = 8×10⁻⁵, P_interaction = 0.02) in the lifestyle intervention group, but not in the placebo (β = +0.20, SEE±0.22 mg/dl/allele, P = 0.35) or metformin (β = −0.03, SEE±0.22 mg/dl/allele, P = 0.90; P_interaction = 0.64) groups. Similarly, a higher GRS predicted a greater number of baseline-adjusted small LDL particles at 1 year in the lifestyle intervention arm (β = +0.30, SEE±0.012 ln nmol/L/allele, P = 0.01, P_interaction = 0.01) but not in the placebo (β = −0.002, SEE±0.008 ln nmol/L/allele, P = 0.74) or metformin (β = +0.013, SEE±0.008 nmol/L/allele, P = 0.12; P_interaction = 0.24) groups. Our findings suggest that a high genetic burden confers an adverse lipid profile and predicts attenuated response in LDL-C levels and small LDL particle number to dietary and physical activity interventions aimed at weight loss.

Vyšlo v časopise: Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program. PLoS Genet 8(8): e32767. doi:10.1371/journal.pgen.1002895
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002895

Souhrn

Zdroje

1. DownsJR, ClearfieldM, WeisS, WhitneyE, ShapiroDR, et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615–1622.

2. SacksFM, PfefferMA, MoyeLA, RouleauJL, RutherfordJD, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001–1009.

3. ShepherdJ, CobbeSM, FordI, IslesCG, LorimerAR, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301–1307.

4. NamboodiriKK, KaplanEB, HeuchI, ElstonRC, GreenPP, et al. (1985) The Collaborative Lipid Research Clinics Family Study: biological and cultural determinants of familial resemblance for plasma lipids and lipoproteins. Genet Epidemiol 2: 227–254.

5. Yu-PothS, ZhaoG, EthertonT, NaglakM, JonnalagaddaS, et al. (1999) 'Effects of the National Cholesterol Education Programs Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 69: 632–646.

6. KrausWE, HoumardJA, DuschaBD, KnetzgerKJ, WhartonMB, et al. (2002) Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 347: 1483–1492.

7. CederbergH, SaukkonenT, LaaksoM, JokelainenJ, HarkonenP, et al. (2010) Postchallenge Glucose, HbA1c, and Fasting Glucose as Predictors of Type 2 Diabetes and Cardiovascular Disease: A 10-year Prospective Cohort Study. Diabetes Care

8. BenjaminSM, ValdezR, VinicorF (2002) Diabetes prevention. N Engl J Med 346: 1829–;–1830 author reply 18291830.

9. ChasmanDI, PareG, MoraS, HopewellJC, PelosoG, et al. (2009) Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet 5: e1000730 doi:10.1371/journal.pgen.1000730.

10. KathiresanS, WillerCJ, PelosoGM, DemissieS, MusunuruK, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41: 56–65.

11. TeslovichTM, MusunuruK, SmithAV, EdmondsonAC, StylianouIM, et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466: 707–713.

12. KathiresanS, MelanderO, AnevskiD, GuiducciC, BurttNP, et al. (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358: 1240–1249.

13. KitabchiAE, TemprosaM, KnowlerWC, KahnSE, FowlerSE, et al. (2005) Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54: 2404–2414.

14. YazdanyarA, YeangC, JiangXC (2011) Role of phospholipid transfer protein in high-density lipoprotein- mediated reverse cholesterol transport. Curr Atheroscler Rep 13: 242–248.

15. VoightBF, PelosoGM, Orho-MelanderM, Frikke-SchmidtR, BarbalicM, et al. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet

16. De BackerG, AmbrosioniE, Borch-JohnsenK, BrotonsC, CifkovaR, et al. (2004) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 173: 381–391.

17. RatnerR, GoldbergR, HaffnerS, MarcovinaS, OrchardT, et al. (2005) Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28: 888–894.

18. DespresJP (2003) Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 29: 6S53–61.

19. KeysA (1965) Effects of Different Dietary Fats on Plasma-Lipid Levels. Lancet 1: 318–319.

20. CorellaD, OrdovasJM (2009) Nutrigenomics in cardiovascular medicine. Circ Cardiovasc Genet 2: 637–651.

21. BernsteinMS, CostanzaMC, JamesRW, MorrisMA, CambienF, et al. (2003) ×No physical activityCETP 1b.-629 interaction effects on lipid profile. Med Sci Sports Exerc 35: 1124–1129.

22. KilpelainenTO, LakkaTA, LaaksonenDE, MagerU, SalopuroT, et al. (2008) Interaction of single nucleotide polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome: The Finnish Diabetes Prevention Study. Metabolism 57: 428–436.

23. NettletonJA, SteffenLM, SchulzeMB, JennyNS, BarrRG, et al. (2007) Associations between markers of subclinical atherosclerosis and dietary patterns derived by principal components analysis and reduced rank regression in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr 85: 1615–1625.

24. SpielmannN, LeonAS, RaoDC, RiceT, SkinnerJS, et al. (2007) CETP genotypes and HDL-cholesterol phenotypes in the HERITAGE Family Study. Physiol Genomics 31: 25–31.

25. Teran-GarciaM, RankinenT, KozaRA, RaoDC, BouchardC (2005) Endurance training-induced changes in insulin sensitivity and gene expression. Am J Physiol Endocrinol Metab 288: E1168–1178.

26. TodorovaB, KubaszekA, PihlajamakiJ, LindstromJ, ErikssonJ, et al. (2004) The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 89: 2019–2023.

27. TuckerAJ, MackayKA, RobinsonLE, GrahamTE, BakovicM, et al. (2010) The effect of whole grain wheat sourdough bread consumption on serum lipids in healthy normoglycemic/normoinsulinemic and hyperglycemic/hyperinsulinemic adults depends on presence of the APOE E3/E3 genotype: a randomized controlled trial. Nutr Metab (Lond) 7: 37.

28. ZhangC, Lopez-RidauraR, RimmEB, RifaiN, HunterDJ, et al. (2005) −→Interactions between the 514CT polymorphism of the hepatic lipase gene and lifestyle factors in relation to HDL concentrations among US diabetic men. Am J Clin Nutr 81: 1429–1435.

29. WillerCJ, SannaS, JacksonAU, ScuteriA, BonnycastleLL, et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40: 161–169.

30. SandhuMS, WaterworthDM, DebenhamSL, WheelerE, PapadakisK, et al. (2008) LDL-cholesterol concentrations: a genome-wide association study. Lancet 371: 483–491.

31. Mayer-DavisEJ, SparksKC, HirstK, CostacouT, LovejoyJC, et al. (2004) Dietary intake in the diabetes prevention program cohort: baseline and 1-year post randomization. Ann Epidemiol 14: 763–772.

32. JablonskiKA, McAteerJB, de BakkerPI, FranksPW, PollinTI, et al. (2010) Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59: 2672–2681.

33. The Diabetes Prevention Program Research Group (1999) Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22: 623–634.

34. KnowlerWC, Barrett-ConnorE, FowlerSE, HammanRF, LachinJM, et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403.

35. WarnickGR (1986) Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol 129: 101–123.

36. WarnickGR, BendersonJ, AlbersJJ (1982) +Dextran sulfate-Mg2 precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 28: 1379–1388.

37. FriedewaldWT, LevyRI, FredricksonDS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502.

38. Hainline AJ, Karon J, Lippel K (1983) Manual of Laboratory Operations. 2nd ed. . Washington, DC, US.: Lipid Research Clinics Program, Lipid and Lipoprotein Analysis, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health

39. OtvosJD (2002) Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48: 171–180.

40. TangK, FuDJ, JulienD, BraunA, CantorCR, et al. (1999) Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci U S A 96: 10016–10020.

41. Fontaine-BissonB, RenstromF, RolandssonO, PayneF, HallmansG, et al. (2010) Evaluating the discriminative power of multi-trait genetic risk scores for type 2 diabetes in a northern Swedish population. Diabetologia

42. MooreAF, JablonskiKA, McAteerJB, SaxenaR, PollinTI, et al. (2008) Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 57: 2503–2510.

43. GoodmanSN, BerlinJA (1994) The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 121: 200–206.

44. SmithAH, BatesMN (1992) Confidence limit analyses should replace power calculations in the interpretation of epidemiologic studies. Epidemiology 3: 449–452.

45. DetskyAS, SackettDL (1985) “”?When was a negative clinical trial big enough How many patients you needed depends on what you found. Arch Intern Med 145: 709–712.

46. GreenlandS (1988) On sample-size and power calculations for studies using confidence intervals. Am J Epidemiol 128: 231–237.